Search

everythinglearnresearchcommunity

for

Search:↓

OP noticed fuller and thicker hair after almost 4 months of using GHK-Cu, a copper-binding peptide, through subcutaneous injections. Some users were skeptical, questioning the authenticity and potential commercial intent behind the post.

A user's success in hair regrowth after taking oral and topical medications, such as minoxidil and dutasteride, and using microneedling. Other users shared their experiences and advice with treatments used to reverse hair loss.

A user is seeking advice on making a topical bicalutamide solution as an alternative to RU58841 for hair loss, while already using dutasteride and minoxidil. They are considering crushing bicalutamide pills and adding them to their minoxidil.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.

The conversation is about using DIY copper peptide (GHK CU) serum for microneedling to address hair loss, with additional treatments including Nizoral for DHT reduction and red light therapy. The user is considering adding Minoxidil but is concerned due to having cats.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

The conversation discusses a 4-month hair loss treatment progress using RU58841, topical Minoxidil, ketoconazole shampoo, and micro-needling. The user shares progress pictures taken at the start, after 1 month, and the current state, all under the same conditions.

A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

The conversation is about a user experiencing positive hair regrowth results using 1mg of dutasteride, 10% minoxidil, and occasional microneedling, after unsatisfactory results with finasteride. Other users express interest in switching to dutasteride and share similar sentiments about finasteride.

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.

A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.

A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.

The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

User shared 8-month hair loss treatment progress using topical fin/min, topical dut, mk677, RU, and microneedling. They experienced watery semen as a side effect but saw significant improvement in hair growth.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

A user experienced severe scalp itching with MPB and found Nizoral ineffective. A doctor diagnosed seborrheic eczema and prescribed Betacap, which relieved the itching.

The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.

Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.

The user reported significant hair regrowth after one month using Cécred edge drops, microneedling, and finasteride, despite skepticism from others. They had previously tried minoxidil, finasteride, PRP, and other treatments with limited success.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

The conversation discusses hair regrowth progress using topical dutasteride with cetirizine, laser therapy, and growth serum. The user observes miniaturized, vellus hairs on the scalp.